Retroperitoneal Fibrosis Clinical Trial
Official title:
Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria
Inflammatory aortitis probably represents a heterogeneous group, and the clinical experience
accumulated over the last ten years, shared by the experts of the subject, is that the
initial clinical, biological or radiological characteristics should make it possible to
differentiate them and dismember the Nosological field.
This will be an essential first step before studying prognosis, risk factors, and
therapeutic options.
The search for diagnostic criteria on a large series, similar to the study of classification
of vascularites of the ACR in 1990, should make it possible to homogenize the diagnoses for
the different teams working on the subject, and to begin work Collaborations, which alone
can improve patient care in the future.
Status | Recruiting |
Enrollment | 206 |
Est. completion date | July 8, 2020 |
Est. primary completion date | July 8, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Cases : - All cases of idiopathic aortitis and retroperitoneal fibrosis followed in participating centers over the past 15 years will be collected. - Witnesses : - Group 1: non-idiopathic inflammatory aortitis: all cases of inflammatory aortitis (apart from idiopathic aortites and isolated retroperitoneal fibrosis) followed in the participating centers over the last 15 years will be collected. - Group 2: subjects with noninflammatory aortic disease, atheromatous type or annulo-ectasitic disease, matched by age and sex with cases. This group will be used to define the differential characteristics between idiopathic aortitis and noninflammatory aortic pathology. - Group 3: This group will include control subjects aimed at defining radiological normality criteria according to age and sex. As the images are machine-dependent, group 3 controls will be randomly selected from the radiology departments that have performed the scanner or MRI of the corresponding control. Exclusion Criteria: - Patients under 18 years of age |
Country | Name | City | State |
---|---|---|---|
France | CHU Amiens Picardie | Amiens | Picardie |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire, Amiens |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Analyze the management of patients with aortic and retroperitoneal fibrosis | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00440349 -
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
|
Phase 2 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT04047576 -
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
|
Phase 2/Phase 3 | |
Completed |
NCT02705638 -
Treatment of IgG4-Related Disease With Revlimid and Rituximab
|
Phase 1 | |
Completed |
NCT01584388 -
Rituximab in IgG4-related Disease: A Phase 1-2 Trial
|
Phase 1/Phase 2 |